Scribe Therapeutics
Ejecutivos
Ver el organigrama con sus 14 ejecutivos principales
Biografías más buscadas en Scribe Therapeutics
- Benjamin Oakes, Chief Executive Officer and Director
- Behzad Aghazadeh, Director
- Vijay Pande, Director
Recientes movimientos de ejecutivos en Scribe Therapeutics
- Maria Mirotsou, se ha incorporado a la empresa como Vice President of Discovery Biology (noticia publicada el 21 de diciembre de 2023).
- Aarif Khakoo, se ha incorporado a la empresa como Chief Scientific Officer and Head of Research and Development (noticia publicada el 21 de diciembre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en Scribe Therapeutics.
Biotecnología
Scribe Therapeutics tiene 2.284 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Transcarent acaba de anunciar una recaudación de fondos de 126 millones de dólares. (publicado el 2 de mayo de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado el 2 de mayo de 2024).
- Enlaza Therapeutics acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 2 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Scribe Therapeutics
- Press Release – Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting • Scribe
- Press Release – Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference • Scribe
- Press Release – Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target • Scribe
- Press Release – Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Scribe
- Press Release – Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology • Scribe
- A decade later, biotech’s CRISPR revolution is still going strong
- Press Release – Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases • Scribe
- Press Release – Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting • Scribe
- Press Release – Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days • Scribe
- Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
- View more press releases Close
Redes sociales sobre Scribe Therapeutics
- Scribe Therapeutics en Wikipedia, Google News y Yahoo Finance
- Scribe Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Carl Gordon 
Llame a Scribe Therapeutics al +1 510...
